We investigated age and performance in distance-limited ultra-marathons held from 50 km to 1,000 km. Age of peak running speed and running speed of the fastest competitors from 1969 to 2012 in 50 km, 100 km, 200 km and 1,000 km ultra-marathons were analyzed using analysis of variance and multi-level regression analyses. The ages of the ten fastest women ever were 40 ± 4 yrs (50 km), 34 ± 7 yrs (100 km), 42 ± 6 yrs (200 km), and 41 ± 5 yrs (1,000 km). The ages were significantly different between 100 km and 200 km and between 100 km and 1,000 km. For men, the ages of the ten fastest ever were 34 ± 6 yrs (50 km), 32 ± 4 yrs (100 km), 44 ± 4 yrs (200 km), and 47 ± 9 yrs (1,000 km). The ages were significantly younger in 50 km compared to 100 km and 200 km and also significantly younger in 100 km compared to 200 km and 1,000 km. The age of the annual ten fastest women decreased in 50 km from 39 ± 8 yrs (1988) to 32 ± 4 yrs (2012) and in men from 35 ± 5 yrs (1977) to 33 ± 5 yrs (2012). In 100 km events, the age of peak running speed of the annual ten fastest women and men remained stable at 34.9 ± 3.2 and 34.5 ± 2.5 yrs, respectively. Peak running speed of top ten runners increased in 50 km and 100 km in women (10.6 ± 1.0 to 15.3 ± 0.7 km/h and 7.3 ± 1.5 to 13.0 ± 0.2 km/h, respectively) and men (14.3 ± 1.2 to 17.5 ± 0.6 km/h and 10.2 ± 1.2 to 15.1 ± 0.2 km/h, respectively). In 200 km and 1,000 km, running speed remained unchanged. In summary, the best male 1,000 km ultra-marathoners were ~15 yrs older than the best male 100 km ultra-marathoners and the best female 1,000 km ultra-marathoners were ~7 yrs older than the best female 100 km ultra-marathoners. The age of the fastest 50 km ultra-marathoners decreased across years whereas it remained unchanged in 100 km ultra-marathoners. These findings may help athletes and coaches to plan an ultra-marathoner’s career. Future studies are needed on the mechanisms by which the fastest runners in the long ultra-marathons tend to be older than those in shorter ultra-marathons.

Distanzierung-und Hygienemassnahmen sind gegen Influenza und COVID-19 präventiv wirksam. Bei hospitalisierten COVID-19-Patient/-innen mit Pneumonie kommt zurzeit eine Therapie mit Dexamethason mit/ohne Remdesivir in Frage. Venöse thromboembolische Ereignisse sollen bei COVID-19 niederschwellig gesucht und vorgebeugt werden. Eine wirksame und sichere SARS-CoV-2-Impfung stellt eine enorme Herausforderung dar. Wahrscheinlich werden wir noch jahrelang mit SARS-CoV-2 leben müssen.

Pendant combien de temps les patient.e.s COVID-19 sont-ils contagieux.eses?